Lizzy Lawrence leads STAT’s coverage of the Food and Drug Administration. She was previously a medical devices reporter. You can reach Lizzy on Signal at lizzylaw.53. WASHINGTON — The Food and Drug ...

Social media companies and their respective algorithms have repeatedly been accused of fueling political polarization by promoting divisive content on their platforms. Now, two U.S. Senators have ...

This issue is preventing our website from loading properly. Please review the following troubleshooting tips or contact us at [email protected]. By submitting your ...

The next phase of the Gaza peace plan brokered by President Trump moved forward significantly on Monday as Hamas released all of the 20 living Israeli hostages in exchange for hundreds of Palestinian ...

Saddle systems improve every year. What once seemed like a niche piece of gear that lived in the periphery of more mainstream whitetail hunting alternatives, saddle hunting is the beneficiary of the ...

TOLEDO, Ohio (WTVG) - 13abc is announcing changes to its CW13 fall 2025 television lineup, including the addition of two additional hours of news programming. Local News Live Anchor and National ...

Why are trips to the grocery store always so chaotic? Even if you go in with a shopping list, it’s easy to get distracted by sales or seasonal snacks, and before you know it, your cart is full of ...

Julianne Geiger is a veteran editor, writer and researcher for Oilprice.com, and a member of the Creative Professionals Networking Group. Venture Global has quietly begun producing LNG from Phase 2 of ...

Maridebart cafraglutide showed up to 19.9% weight loss in obesity and 17% in obesity-diabetes patients in a phase 2 trial. The drug's 21-day half-life, combining GLP-1 receptor agonism and GIP ...

Ambitious MMORPG Ashes of Creation is gearing up for the next stage of its ongoing alpha test, and there's a lot to look forward to. In a new development livestream, Intrepid Studios reveals a big ...

Semaglutide at a dose of 2.4 mg has established weight-loss and cardiovascular benefits, and cagrilintide at a dose of 2.4 mg has shown promising results in early-phase trials; the efficacy of the ...